NCT01838954

Brief Summary

Due to constant strain the joints of the hands are frequently affected by osteoarthritis (OA). Short-wave diathermy (SWD) is a form of electromagnetic therapy, which causes movement of ions, distortion of molecules, and creation of eddy currents and as a result heat is produced in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain. Since the available studies were performed to study the large weight-bearing joints only, there is a lack in scientific evidence for the efficacy of SWD in hand OA. The aim of this randomized, double blind, placebo-controlled study is to evaluate the effect of SWD on: joint function in patients with hand OA. joint pain in patients with hand OA. grip strength in patients with hand OA. quality of live in patients with hand OA.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

April 16, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 24, 2013

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

April 10, 2015

Status Verified

April 1, 2015

Enrollment Period

4.1 years

First QC Date

April 16, 2013

Last Update Submit

April 9, 2015

Conditions

Keywords

hand osteoarthritisshort-wave diathermy

Outcome Measures

Primary Outcomes (1)

  • change in joint function in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)

    week 0, week 4, week 12

Secondary Outcomes (3)

  • change in joint pain in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)

    week 0, week 4, week 12

  • change in grip strength in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)

    week 0, week 4, week 12

  • quality of live in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)

    week 0, week 4, week 12

Study Arms (2)

Short-wave diathermy

ACTIVE COMPARATOR

Short-wave diathermy device turned on

Device: Short-wave diathermy

control

PLACEBO COMPARATOR

Short-wave diathermy device turned off

Interventions

Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.

Also known as: Ultratherm (Siemens) model 808i
Short-wave diathermy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females \> 18 years of age. All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study.
  • Persistent or transient pain/aching/stiffness in at least one DIP and/or PIP joint with or without bony swelling
  • Hand X-ray showing alterations typical for OA
  • If NSAIDs are used to treat finger joint pain dosage must be stable for at least 4 weeks
  • Able and willing to give written informed consent and to comply with the requirements of the study protocol.

You may not qualify if:

  • Prior treatment with any investigational agent within 30 days, or five half lives of the product, whichever is longer.
  • Patients suffering from chronic inflammatory rheumatic disease (e.g. rheumatoid arthritis or positive rheumatoid factor or positive anti-CCP antibodies, seronegative spondylarthropathy, haemochromatosis, gout, chondrocalcinosis or other auto-immune diseases
  • Stable dosage for at least 3 months with chondroitin sulfate, glucosamine, biphosphonate, corticosteroids, tetracyclines and estrogens is allowed.
  • Prior use of any immunomodulating drug with possible effects on pro-inflammatory cytokine metabolism within 90 days a.o. corticosteroids, methotrexate, sulfasalazine, leflunomide, d-penicillamin, anti-malarials, cytotoxic drugs, TNF blocking agents
  • If the patient is of child-bearing age, he/she must use effective means of contraception during the study.
  • Use of anticoagulants (cumarins or low-molecular-weight-heparins)
  • Subjects with hand OA showing or having suffered from transient inflammatory attacks of the IPJs characteristic for what has been termed 'inflammatory' or 'erosive' hand OA.
  • Patient who has a known blood coagulation disorder
  • metall implants (such as joint endoprothesis, pace-maker, implantable cardioverter/defibrillator, stents), piercings have to be removed prior to SWD treatment
  • History of cancer or lymphoproliferative disease
  • Comorbidities: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA III, IV), recent stroke (within three months), uncontrolled hypertension (defined as screening systolic blood pressure \> 160 mmHg or screening diastolic blood pressure \> 100 mmHg), severe pulmonary disease requiring hospitalization or supplemental oxygen
  • Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.
  • Female subjects who are breast-feeding.
  • History of clinically significant drug or alcohol abuse in the last year.
  • Medical history of systemic lupus erythematosus or other connective tissue disease, RA, reactive arthritis, psoriasis
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna

Vienna, Vienna, 1090, Austria

RECRUITING

Study Officials

  • Klaus Bobacz, MD

    Medical University of Vienna

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

April 16, 2013

First Posted

April 24, 2013

Study Start

March 1, 2012

Primary Completion

April 1, 2016

Study Completion

September 1, 2016

Last Updated

April 10, 2015

Record last verified: 2015-04

Locations